Literature DB >> 28858156

Comparison of Efficacy and Complications of Cyclophotocoagulation and Second Glaucoma Drainage Device After Initial Glaucoma Drainage Device Failure.

Margaret Y Wang1, Kishan Patel, Lauren S Blieden, Alice Z Chuang, Laura A Baker, Nicholas P Bell, Robert M Feldman.   

Abstract

PURPOSE: Compare intraocular pressure (IOP) control and complication rates of a second glaucoma drainage device (GDD) to diode transscleral cyclophotocoagulation (TSCPC) following failure of an initial GDD. PATIENTS AND METHODS: Eyes with 1 GDD that required a second GDD or TSCPC for glaucoma control were included. Exclusion criteria were a cyclodestructive procedure before initial GDD, no light perception vision, or follow-up <1 year. Failure was defined as ≥1 of (1) reoperation for lowering IOP; (2) explantation of second GDD; (3) persistent hypotony; (4) use of oral carbonic anhydrase inhibitor for lowering IOP in the study eye; or (5) loss of light perception. Reoperation for lowering IOP included additional GDD implantation or additional cyclodestruction, except if additional cyclodestruction was within 6 months of the initial session.
RESULTS: A total of 75 eyes (35 in second GDD; 40 in TSCPC) were included (mean follow-up, 25.5 mo). Both procedures lowered IOP [-11.4 mm Hg (±13.6) for second GDD and -7.8 mm Hg (±11.8) for TSCPC groups] and decreased the number of IOP-lowering medications at the last visit. The second GDD group had significantly greater mean survival time [45.0 mo (±4.2)] than the TSCPC group [26.5 mo (±2.8)] but significantly more postoperative complications (60% of eyes) and non-IOP-related procedures (40% of eyes) than the TSCPC group (20% for postoperative complications and 18% for non-IOP-related procedures).
CONCLUSIONS: Although both second procedures are efficacious in lowering IOP and number of IOP-lowering medications, TSCPC failed earlier, whereas a second GDD had significantly more complications.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28858156     DOI: 10.1097/IJG.0000000000000766

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  6 in total

1.  Safety and Efficacy of Second Ahmed Valve Implant in Refractory Glaucoma.

Authors:  Chiara Posarelli; Mario Damiano Toro; Robert Rejdak; Tomasz Żarnowski; Dorota Pożarowska; Antonio Longo; Mario Miccoli; Marco Nardi; Michele Figus
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

Review 2.  Cyclodestructive Procedures in Glaucoma: A Review of Current and Emerging Options.

Authors:  Anna I Dastiridou; Andreas Katsanos; Philippe Denis; Brian A Francis; Dimitrios G Mikropoulos; Miguel A Teus; Anastasios-Georgios Konstas
Journal:  Adv Ther       Date:  2018-11-17       Impact factor: 3.845

3.  Outcomes of Baerveldt Glaucoma Drainage Devices in Pediatric Eyes.

Authors:  Adam Jacobson; Cagri G Besirli; Brenda L Bohnsack
Journal:  J Glaucoma       Date:  2021-12-21       Impact factor: 2.290

4.  A Pilot Study Assessing Treatment Outcomes in Neovascular Glaucoma Using Ahmed Glaucoma Valve with and without Cyclophotocoagulation.

Authors:  Richard L Ford; O'Rese J Knight; Meredith R Klifto; Alice Yang Zhang; Christopher A Wiesen; David Fleischman
Journal:  J Curr Glaucoma Pract       Date:  2022 Jan-Apr

5.  Outcomes of the Second Aqueous Shunt Implant Versus Transscleral Cyclophotocoagulation Treatment Study: A Randomized Comparative Trial.

Authors:  Robert M Feldman; Alice Z Chuang; Steve L Mansberger; Angelo P Tanna; Lauren S Blieden; Nicholas P Bell; Ronald L Gross; Louis R Pasquale; David S Greenfield; Jeffrey M Liebmann; Robert N Weinreb
Journal:  J Glaucoma       Date:  2022-07-21       Impact factor: 2.290

6.  Surgical Outcomes of a Second Ahmed Glaucoma Valve Implantation in Asian Eyes with Refractory Glaucoma.

Authors:  Sze Chuan Ong; Maria Cecilia Aquino; Paul Chew; Victor Koh
Journal:  J Ophthalmol       Date:  2020-03-23       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.